GSK3494245

GSK3494245 is an orally active small molecule drug developed for the treatment of visceral leishmaniasis (VL), a potentially fatal infectious disease caused by Leishmania parasites. The compound acts as a selective inhibitor of the chymotrypsin-like activity of the β5 subunit in the *Leishmania donovani* proteasome. By disrupting protein recycling and removal in the parasite through proteasome inhibition—specifically targeting *L. donovani*—the drug leads to parasite death. Preclinical studies demonstrated efficacy and safety in animal models; early clinical trials have focused on evaluating its safety and pharmacokinetics in healthy volunteers[2][3][4][6][8].

Other names

N-(4-Fluoro-3-(3-morpholinoimidazo(1,2-a)pyrimidin-7-yl)phenyl)pyrrolidine-1-carboxamideN-(4-fluoro-3-(3-morpholinoimidazo[1,2-a]pyrimidin-7-yl)phenyl)pyrrolidine-1-carboxamide1-Pyrrolidinecarboxamide N-(4-fluoro-3-(3-(4-morpholinyl)imidazo(1,2-a)pyrimidin-7-yl)phenyl)-UNII-T7XAE9Y6B9UNII-T-7XAE9Y6B9UNII-T 7XAE9Y6B9CHEMBL5095239CHEMBL-5095239CHEMBL 5095239SCHEMBL18495650SCHEMBL-18495650SCHEMBL 18495650BDBM50601512BDBM-50601512BDBM 50601512MS-27077MS27077MS 27077HY-127102HY127102HY 127102CS-0093101CS0093101CS 0093101